Chemoradiation May Help Increase Cancer Survival Rates
By MedImaging International staff writers Posted on 07 Mar 2016 |
The addition of chemotherapy to radiation therapy (RT) improves survival rates among a subset of septuagenarian head and neck cancer patients, according to a new study.
Researchers at the University of Colorado (Anschutz; Aurora, USA) queried the US National Cancer Data Base (NCDB) for records of patients older than 70 years who were treated for non-metastatic head and neck squamous cell carcinoma (HNSCC) cancers between 1998 and 2011. The patients were then divided into two groups, based on whether or not patients received chemotherapy concurrent with RT (CRT), defined as beginning a course of chemotherapy within 14 days of RT.
The results showed that 68% of the patients received RT alone, and 32% received CRT. When compared to RT alone, CRT demonstrated a survival benefit among septuagenarians that was similar to that of younger HNSCC patients with limited comorbidity and later-stage disease. Specifically, CRT was beneficial for patients 71–79 years of age with low comorbidity scores and advanced disease stage. The study was presented at the annual Multidisciplinary Head and Neck Cancer Symposium, held during February 2016 in Scottsdale (AZ, USA).
“Because the toxicity of concurrent chemoradiation is greater than radiation alone for definitive HNSCC treatment, many clinicians have reservations about offering CRT for elderly head and neck cancer patients,” said senior author and study presenter Sana Karam, MD, PhD, assistant professor of radiation oncology at Anschutz. “However, in the era of improved radiation techniques, improved systemic therapy and better supportive care, we find that CRT does, in fact, improve survival for a large segment of this population.”
HNSCC develops in the mucous membranes of the mouth, nose, and throat, and is classified by its location: the oral cavity, the oropharynx, the nasal cavity and paranasal sinuses, the nasopharynx, the larynx, and the hypopharynx. The can also be grouped into wider oropharyngeal, laryngeal, and hypopharyngeal cancers. Depending on the location, the cancer can cause ulcerations, unusual bleeding or pain, sinus congestions, pain when swallowing or difficulty swallowing, a hoarse voice, difficulty breathing, or enlarged lymph nodes.
Related Links:
University of Colorado
Researchers at the University of Colorado (Anschutz; Aurora, USA) queried the US National Cancer Data Base (NCDB) for records of patients older than 70 years who were treated for non-metastatic head and neck squamous cell carcinoma (HNSCC) cancers between 1998 and 2011. The patients were then divided into two groups, based on whether or not patients received chemotherapy concurrent with RT (CRT), defined as beginning a course of chemotherapy within 14 days of RT.
The results showed that 68% of the patients received RT alone, and 32% received CRT. When compared to RT alone, CRT demonstrated a survival benefit among septuagenarians that was similar to that of younger HNSCC patients with limited comorbidity and later-stage disease. Specifically, CRT was beneficial for patients 71–79 years of age with low comorbidity scores and advanced disease stage. The study was presented at the annual Multidisciplinary Head and Neck Cancer Symposium, held during February 2016 in Scottsdale (AZ, USA).
“Because the toxicity of concurrent chemoradiation is greater than radiation alone for definitive HNSCC treatment, many clinicians have reservations about offering CRT for elderly head and neck cancer patients,” said senior author and study presenter Sana Karam, MD, PhD, assistant professor of radiation oncology at Anschutz. “However, in the era of improved radiation techniques, improved systemic therapy and better supportive care, we find that CRT does, in fact, improve survival for a large segment of this population.”
HNSCC develops in the mucous membranes of the mouth, nose, and throat, and is classified by its location: the oral cavity, the oropharynx, the nasal cavity and paranasal sinuses, the nasopharynx, the larynx, and the hypopharynx. The can also be grouped into wider oropharyngeal, laryngeal, and hypopharyngeal cancers. Depending on the location, the cancer can cause ulcerations, unusual bleeding or pain, sinus congestions, pain when swallowing or difficulty swallowing, a hoarse voice, difficulty breathing, or enlarged lymph nodes.
Related Links:
University of Colorado
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment